Growing at an annualized rate of over 35%, the large volume wearable injectors market for delivery of non-insulin drugs is projected to be worth USD 600 million by 2030, claims Roots Analysis
Roots Analysis has announced theaddition of “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal andContinuous Delivery Devices” reportto its list of offerings.
114
views

Over the years, a rise in preference for self-administrabledrugs / therapies has resulted in an increasing demand for user-friendly drugdelivery solutions that are not only safe and efficient, but also promotetherapy adherence

 

London

 

Roots Analysis has announced theaddition of Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal andContinuous Delivery Devices reportto its list of offerings.

 

The wide-spreadprevalence of chronic diseases has compelled drug developers to innovate anddesign  better, more advanced healthcaresolutions. Large volume wearable injectors were developed to specificallyaddress certain challenges associated with the administration of high volumeformulations, viscous drug solutions andcater to frequent dosing requirements of patients suffering from chronic healthconditions.

 

To order this 500+ pagereport, which features 175+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html

 

 

KeyMarket Insights 

 

More than25 large volume wearable injectors are presently available / under development forthe administration of drugs, excluding insulin

Over 45% ofthe abovementioned devices are capable of delivering bolus doses, followed bydevices designed for continuous dosing at pre-programmed rates (15 %). These devicesare powered by a diverse variety of actuation mechanisms, including rotary pumps,cells / expanded batteries, springs, osmotic pressure and liquefied gas. It isworth noting that over 15+ known drug-device combinations are commercialized /under development.

 

Forinsulin delivery alone, there are 30+ large volume wearable injectors available/ under development

It isworth highlighting that nearly 40% of the abovementioned devices presently use advancedalgorithms in order to automate the delivery of insulin, based on integrated continuousblood glucose monitoring systems. Of these, majority (23%) use the hybridclosed loop system. Over 80% of such devices have special connectivity featuresthat enable better dosage monitoring.

 

More than200 biologics / small molecule drugs were identified as likely products to bedeveloped in combination with large volume wearable injectors

The reportprovides insights on over 800 marketed drugs / therapies and pipelinecandidates, assessing the likelihood of whether they can be developed incombination with large volume wearable injectors. The analysis takes intoconsideration current phase of development of the drug, its dosage, doseconcentration, route of administration, type of dose and information on drugsales (for marketed drugs).

 

Nearly90 partnerships have been signed by developers of large volume wearableinjectors between 2015 and 2020 (till March)

It isworth noting that more than 55% deals were established post 2017, indicating anincrease in the partnership activity within this domain. Majority of partnershipdeals were product / technology integration agreements (29%), followed by dealsfocused on product development and commercialization (23%), mergers andacquisitions (12%), and product distribution (12%).

 

NorthAmerica and Europe are anticipated to capture over 60% of the market share, interms of revenues generated from sales of non-insulin drug delivery devices, in2030

By 2030,46% of revenues are expected to be generated from the sales of large volumewearable injectors intended for the treatment of neurological disorders, followedby products for oncological disorders (27%), cardiovascular disorders (25%) andinfectious diseases (2%).

 

Thelarge volume wearable injectors market for insulin is anticipated to be worth overUSD 2.7 billion by 2030

NorthAmerica presently dominates the global insulin market, consequently the regionis expected to capture the majority share (50%) in terms of revenues fromwearable injector sales. It is worth highlighting that the market in Asia-pacific is anticipated to growat a relatively faster pace.

 

To request a sample copy /brochure of this report, please visit this - https://www.rootsanalysis.com/reports/238/request-sample.html

   

Key Questions Answered

§ Who are the leading developers oflarge volume wearable devices? 

§ What are the prevalent trendswithin the large volume wearable injectors market?

§ Which drug candidates are suitedfor delivery via large volume wearable injectors?

§ Who are the key contract serviceproviders in this domain?

§ What are the various regulatory guidelinesissued for medical devices across different regions?

§ How is the current and futuremarket opportunity likely to be distributed across key market segments?

 

 

The financial opportunity withinthe large volume wearable injectors market (for delivery of non-insulin andinsulin drugs) has been analyzed across the following segments:

§ Type of Device

  • Patch Pump / Injectors
  • Infusion Pump / Injectors

 

§ Product Usability

  • Disposable
  • Re-usable

 

§ Therapeutic Area (fornon-insulin drugs)

  • Neurological Disorders
  • Cardiovascular Disorders
  • Oncological Disorders
  • Infectious Disorders

 

§ Key geographicalregions 

  • North America
  • Europe
  • Asia Pacific and Rest of the World

 

 

Thereport features inputs from eminent industry stakeholders, according to whom, largevolume injectors are generally preferred for the delivery of biologics, which cannotbe easily administered orally. The report includes detailed transcripts ofdiscussions held with the following experts:

§ Mark Banister (CEO, Medipacs)

§ Michael Hooven (CEO, Enable Injections)

§ Jesper Roested (CEO, Subcuject)

§ Pieter Muntendam (Former Presidentand CEO, scPharmaceuticals)

§ Menachem Zucker (Vice Presidentand Chief Scientist, ElcamMedical)

§ Graham Reynolds (Vice President andGeneral Manager, Biologics, WestPharmaceutical Services)

§ Mindy Katz (Director of Product, Sorrel Medical)

 

 

The research includes detailedprofiles of key players (listed below); each profile features anoverview of the company, its financial information (if available), a description of the product(s)offered, details of recent developments related to large volume wearableinjection devices and an informed future outlook.

§ Becton Dickinson

§ Bespak (subsidiary of ConsortMedical)

§ CeQur

§ Debiotech

§ Eli Lilly

§ Enable Injections

§ Insulet

§ Medtronic

§ PharmaSens

§ Roche

§ SOOIL Development

§ Sonceboz

§ Sensile Medical (acquired byGerresheimer)

§ SteadyMed Therapeutics (acquiredby United Therapeutics)

§ Tandem Diabetes Care

§ Weibel CDS (acquired by SHLMedical)

§ West Pharmaceutical Services

 

For additional details, pleasevisit 

https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
or email 
sales@rootsanalysis.com

 

You may also be interested in thefollowing titles: 

1.     Microneedles andNeedle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms)Market, 2019-2030 [COVID-19 Series]

2.     Global AutoinjectorsMarket (3rd Edition),2020-2030

3.     Prefilled SyringesMarket (5th Edition),2020-2030

 

 

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com